Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Compare

4,005 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SRPT Analyst Ratings

Hold

6 Buy

13 Hold

5 Sell

Based on 24 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$24.35

▲(6.75% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $24.35 with a high forecast of $80.00 and a low forecast of $5.00. The average price target represents a 6.75% change from the last price of $22.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","35":"$35","66":"$66","97":"$97","128":"$128"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,35,66,97,128],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.32,23.987692307692306,28.655384615384616,33.323076923076925,37.99076923076923,42.65846153846154,47.326153846153844,51.99384615384616,56.66153846153846,61.32923076923077,65.99692307692308,70.66461538461539,75.3323076923077,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.32,19.706923076923076,20.093846153846155,20.48076923076923,20.86769230769231,21.254615384615384,21.641538461538463,22.02846153846154,22.415384615384617,22.802307692307693,23.18923076923077,23.576153846153847,23.963076923076926,{"y":24.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.32,18.21846153846154,17.116923076923076,16.015384615384615,14.913846153846155,13.812307692307693,12.71076923076923,11.60923076923077,10.507692307692308,9.406153846153845,8.304615384615385,7.203076923076923,6.1015384615384605,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":122.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 79, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 93, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 84, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 25</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$24.35

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Abrahams

RBC Capital

$16

Hold

-29.86%

Downside

Reiterated

10/22/25

RBC Capital Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)

Mitchell Kapoor

H.C. Wainwright

Sell

-78.08%

Downside

Reiterated

10/22/25

H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Tazeen Ahmad

Bank of America Securities

$16→$18

Sell

-21.09%

Downside

Reiterated

10/22/25

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)We reiterate our Underperform rating with new $18 PO (prev. $16 PO, see below for model changes).

Michael Ulz

Morgan Stanley

$20

Hold

-12.32%

Downside

Reiterated

10/16/25

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and PTC Therapeutics (NASDAQ: PTCT)

Joseph Schwartz

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Sami Corwin

William Blair

―

Hold

―

Reiterated

10/13/25

Cautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus Findings

Gil Blum

Needham

―

Sell

―

Reiterated

10/13/25

Needham Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)We view these preliminary data as encouraging for further evaluation of Sirolimus prophylaxis in mitigating liver toxicity following Elevidys administration. That said, the small sample size and limited inclusion of non-ambulatory patients (only one in the Sirolimus cohort) make it challenging to draw firm conclusions. Sarepta is still awaiting feedback from the FDA regarding its proposal to assess the safety and dystrophin expression of Elevidys with the addition of Sirolimus prophylaxis in a small non-ambulatory cohort of the ENDEA VOR study (see design below). We maintain our Underperform Rating. BLUM, PH.D.

Andreas Argyrides

Oppenheimer

$37

Buy

62.21%

Upside

Reiterated

10/09/25

Oppenheimer Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)We maintain our Outperform rating and $37 PT.

Andrew Tsai

Jefferies

$35

Buy

53.44%

Upside

Reiterated

10/08/25

Sarepta Therapeutics (SRPT) Receives a Buy from JefferiesJefferies analyst Andrew Tsai reiterated a Buy rating and $35.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

Uy Ear

Mizuho Securities

$19

Hold

-16.70%

Downside

Reiterated

10/06/25

Sarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesWe maintain our Neutral and $19 PT for SRPT.

Gavin Clark-Gartner

Evercore ISI

$17

Hold

-25.47%

Downside

Reiterated

09/23/25

Sarepta Therapeutics (SRPT) Receives a Hold from Evercore ISI

Kristen Kluska

Cantor Fitzgerald

$14

Hold

-38.62%

Downside

Reiterated

09/22/25

Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)Cantor Fitzgerald analyst Kristen Kluska reiterated a Neutral rating and $14.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

Debjit Chattopadhyay

Guggenheim

$22

Buy

-3.55%

Downside

Reiterated

09/15/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Hoang

Deutsche Bank

$12

Sell

-47.39%

Downside

Reiterated

08/27/25

Sarepta down 10% on new adverse event report, says Deutsche BankSarepta down 10% on new adverse event report, says Deutsche Bank

Anupam Rama

J.P. Morgan

$24→$18

Hold

-21.09%

Downside

Reiterated

08/26/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Cooper Co (NASDAQ: COO) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Abrahams

RBC Capital

$16

Hold

-29.86%

Downside

Reiterated

10/22/25

RBC Capital Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)

Mitchell Kapoor

H.C. Wainwright

Sell

-78.08%

Downside

Reiterated

10/22/25

H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Tazeen Ahmad

Bank of America Securities

$16→$18

Sell

-21.09%

Downside

Reiterated

10/22/25

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)We reiterate our Underperform rating with new $18 PO (prev. $16 PO, see below for model changes).

Michael Ulz

Morgan Stanley

$20

Hold

-12.32%

Downside

Reiterated

10/16/25

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and PTC Therapeutics (NASDAQ: PTCT)

Joseph Schwartz

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Sami Corwin

William Blair

―

Hold

―

Reiterated

10/13/25

Cautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus Findings

Gil Blum

Needham

―

Sell

―

Reiterated

10/13/25

Andreas Argyrides

Oppenheimer

$37

Buy

62.21%

Upside

Reiterated

10/09/25

Oppenheimer Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)We maintain our Outperform rating and $37 PT.

Andrew Tsai

Jefferies

$35

Buy

53.44%

Upside

Reiterated

10/08/25

Sarepta Therapeutics (SRPT) Receives a Buy from JefferiesJefferies analyst Andrew Tsai reiterated a Buy rating and $35.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

Uy Ear

Mizuho Securities

$19

Hold

-16.70%

Downside

Reiterated

10/06/25

Sarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesWe maintain our Neutral and $19 PT for SRPT.

Gavin Clark-Gartner

Evercore ISI

$17

Hold

-25.47%

Downside

Reiterated

09/23/25

Sarepta Therapeutics (SRPT) Receives a Hold from Evercore ISI

Kristen Kluska

Cantor Fitzgerald

$14

Hold

-38.62%

Downside

Reiterated

09/22/25

Debjit Chattopadhyay

Guggenheim

$22

Buy

-3.55%

Downside

Reiterated

09/15/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Hoang

Deutsche Bank

$12

Sell

-47.39%

Downside

Reiterated

08/27/25

Sarepta down 10% on new adverse event report, says Deutsche BankSarepta down 10% on new adverse event report, says Deutsche Bank

Anupam Rama

J.P. Morgan

$24→$18

Hold

-21.09%

Downside

Reiterated

08/26/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Cooper Co (NASDAQ: COO) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

1 Month

xxx

Success Rate

24/38 ratings generated profit

Average Return

+7.19%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +7.19% per trade.

3 Months

xxx

Success Rate

22/38 ratings generated profit

Average Return

+7.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.40% per trade.

1 Year

Debjit ChattopadhyayGuggenheim

Success Rate

20/38 ratings generated profit

Average Return

+10.47%

reiterated a buy rating last month

Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +10.47% per trade.

2 Years

xxx

Success Rate

17/38 ratings generated profit

Average Return

+8.41%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.74% of your transactions generating a profit, with an average return of +8.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

100

150

156

130

In the current month, SRPT has received 9 Buy Ratings, 43 Hold Ratings, and 12 Sell Ratings. SRPT average Analyst price target in the past 3 months is 24.35.

Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is -$0.70 with a range of -$1.86 to $1.71. The previous quarter’s EPS was $1.89. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SRPT has Preformed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $333.27M with a range of $213.19M to $388.00M. The previous quarter’s sales results were $611.09M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SRPT has Preformed in-line its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 24.35.

What is SRPT’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 6.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Hold which is based on 6 buy ratings, 13 hold ratings and 5 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is 24.35. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents 6.75% Increase from the current price of $22.81.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts